Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

This phase I study will evaluate the feasibility and toxicity of weekly bortezomib in the treatment of relapsed or refractory multiple Myeloma and determine whether a twice-weekly schedule of bortezomib is effective in producing responses in patients with stable disease or progression after weekly bortezomib

Key facts

Study ID

NCT00193557

Run by

SCRI Development Innovations, LLC

People needed

40

Starts

2004-05-01

Expected to finish

2009-01-01

Last updated by the study team

2010-06-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• To be included in this study, you must meet the following criteria:
• Multiple Myeloma
• Received no more than 2 previous treatment regimens for multiple Myeloma
• ECOG performance status 0, 1, or 2
• Serum creatinine < 2.0mg/dL
• calculated or measured creatinine clearance > 30ml/minute
• Measurable or evaluable disease
• Provide written informed consent prior to receiving protocol therapy.

You may not qualify if…

• You cannot participate in this study if any of the following apply to you:
• Moderate or severe peripheral neuropathy
• Other serious medical conditions
• Other active malignancies
• history of treatment for other invasive cancers
• Women who are pregnant or lactating
• Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Where it is running

• Florida Cancer Specialists — Fort Myers, Florida, United States
• Tennessee Oncology, PLLC — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.